VANTRELA ER Drug Patent Profile
✉ Email this page to a colleague
When do Vantrela Er patents expire, and what generic alternatives are available?
Vantrela Er is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-three patent family members in thirteen countries.
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vantrela Er
A generic version of VANTRELA ER was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.
Summary for VANTRELA ER
International Patents: | 33 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VANTRELA ER at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VANTRELA ER
US Patents and Regulatory Information for VANTRELA ER
VANTRELA ER is protected by three US patents.
Patents protecting VANTRELA ER
Abuse resistant drug formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Abuse resistant drug formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Abuse resistant drug formulation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-001 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-003 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-002 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-004 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-003 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VANTRELA ER
When does loss-of-exclusivity occur for VANTRELA ER?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 63172
Estimated Expiration: ⤷ Try a Trial
Patent: 99142
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 15005
Estimated Expiration: ⤷ Try a Trial
Patent: 16598
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 73795
Estimated Expiration: ⤷ Try a Trial
Patent: 00593
Estimated Expiration: ⤷ Try a Trial
Patent: 92341
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 73795
Estimated Expiration: ⤷ Try a Trial
Patent: 00593
Estimated Expiration: ⤷ Try a Trial
Patent: 92341
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 34775
Estimated Expiration: ⤷ Try a Trial
Patent: 93567
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 27128
Estimated Expiration: ⤷ Try a Trial
Patent: 32012
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 57032
Estimated Expiration: ⤷ Try a Trial
Patent: 30572
Estimated Expiration: ⤷ Try a Trial
Patent: 11504455
Estimated Expiration: ⤷ Try a Trial
Patent: 11517654
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 6861
Estimated Expiration: ⤷ Try a Trial
Patent: 09002757
Estimated Expiration: ⤷ Try a Trial
Patent: 10002780
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 73795
Estimated Expiration: ⤷ Try a Trial
Patent: 00593
Estimated Expiration: ⤷ Try a Trial
Patent: 92341
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 73795
Estimated Expiration: ⤷ Try a Trial
Patent: 92341
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 73795
Estimated Expiration: ⤷ Try a Trial
Patent: 92341
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 52033
Estimated Expiration: ⤷ Try a Trial
Patent: 43802
Estimated Expiration: ⤷ Try a Trial
Patent: 11794
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VANTRELA ER around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 2200593 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2009035474 | ⤷ Try a Trial | |
Japan | 2011517654 | ⤷ Try a Trial | |
Portugal | 2073795 | ⤷ Try a Trial | |
Canada | 2663172 | PREPARATION MEDICAMENTEUSE EMPECHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |